Overview

Istradefylline for Parkinson Disease With Cognitive Impairment

Status:
Not yet recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine whether istradefylline improves cognition in individuals with Parkinson disease with cognitive impairment.
Phase:
Phase 2
Details
Lead Sponsor:
Virginia Commonwealth University
Collaborator:
Kyowa Kirin, Inc.
Treatments:
Istradefylline